Which finding is a contraindication for the medication liraglutide?

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and obesity, has a specific contraindication related to the history of thyroid cancer. This medication carries a warning based on studies that have shown an increased risk of thyroid C-cell tumors in rodent models. Due to this potential risk, liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Thus, the presence of a history of thyroid cancer is particularly concerning, as it signifies a potential predisposition to developing similar tumors, making it unsafe for these patients to use liraglutide. It highlights the importance of thorough patient history taking when prescribing medications that may be contraindicated based on previous health conditions.

In contrast, while a history of hypertension, asthma, or heart disease may require careful monitoring or additional considerations when prescribing liraglutide, they do not serve as absolute contraindications for its use.